 |
Journal articles
Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer.
Abstract : Bevacizumab-taxane combinations provide an alternative to chemotherapy doublet regimens in first-line mBC, with equivalent efficacy and potentially lower toxicity. Ongoing trials are investigating the efficacy and safety of bevacizumab in various stages of breast cancer and in breast cancer with a range of hormonal or receptor characteristics.
https://www.hal.inserm.fr/inserm-00484825
Contributor : Philippe Saas <>
Submitted on : Wednesday, May 19, 2010 - 11:54:14 AM
Last modification on : Tuesday, October 27, 2020 - 2:35:52 PM
Contributor : Philippe Saas <>
Submitted on : Wednesday, May 19, 2010 - 11:54:14 AM
Last modification on : Tuesday, October 27, 2020 - 2:35:52 PM
Links full text
